Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 16Neoplasms 14Prostatic Neoplasms 10Hematologic Neoplasms 9Colorectal Neoplasms 8Lung Neoplasms 5Hematopoietic and Lymphatic System Neoplasm 5Squamous Cell Carcinoma of Head and Neck 4Anatomic Stage I Breast Cancer AJCC v8 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Malignant Solid Neoplasm 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Parotid Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Head and Neck Carcinoma 2Glioma 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2COVID-19 2

Interventions

Biopsy 9Specimen Handling 8Magnetic Resonance Spectroscopy 6duvelisib 5Cyclophosphamide 5ruxolitinib 4Vincristine 410-propargyl-10-deazaaminopterin 4pembrolizumab 3X-Rays 3Prednisone 3Etoposide 3Doxorubicin 3tazemetostat 2sodium-iodide symporter 2cemiplimab 2belinostat 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Disulfides 2Cytarabine 2Bortezomib 2Azacitidine 2venetoclax 1talimogene laherparepvec 1romidepsin 1prednylidene 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Standard of Care × 90 days × Clear all
NCT06724237 2026-05-15

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Eastern Cooperative Oncology Group

Phase 3 Recruiting
294 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡